Use of an IL-31 monoclonal antibody for antagonizing signal transduction in spinal cord cells
US9631021B2 · kind B2 · utility
0Cited by
27References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 15, 2016 |
| Grant date | Apr 25, 2017 |
| Priority date | — |
| Expiry date | Apr 15, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.